We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Improving Human Ovarian Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00827476
Recruitment Status : Unknown
Verified January 2009 by Hadassah Medical Organization.
Recruitment status was:  Active, not recruiting
First Posted : January 22, 2009
Last Update Posted : January 22, 2009
Information provided by:

January 21, 2009
January 22, 2009
January 22, 2009
January 2009
January 2012   (Final data collection date for primary outcome measure)
improving folliculogenesis and oocuyte maturation after ovarian transplantation [ Time Frame: 2 years ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Improving Human Ovarian Transplantation
Phase 1 Study to Improve Results of Human Ovarian Transplantation
we will perform xenotransplantation and in vitro culture of ovarian tissue from patients undergoing ovarian cortex cryopreservation.
Ovarian tissue is removed by laparoscopy and only in patients facing premature ovarian failure due to chemotherapy.Tissue for research will consist either of a small portion (<10%) of the cortex for preservation for young women. another source of ovarian tissue for research will be obtained following consent from family of patients who have died of the disease and have previously frozen ovarian tissue.
Early Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Fertility Preservation
Procedure: ovarian transplantation
ovarian xenotransplantation or in vitro culture
Experimental: ovarian transplantation
tissue will be used for xenotransplantation or in vitro culture
Intervention: Procedure: ovarian transplantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
January 2015
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • tissue previously obtained

Exclusion Criteria:

  • no tissue available or no consent
Sexes Eligible for Study: Female
5 Years to 40 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
0530-08-HMO- CTIL
Not Provided
Not Provided
Ariel Revel, Hadassah Medical Organization
Hadassah Medical Organization
Israel Science Foundation
Not Provided
Hadassah Medical Organization
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP